Romyelocel-L

Drug Profile

Romyelocel-L

Alternative Names: CLT-008; hMPC - Cellerant Therapeutics; Human myeloid progenitor cells - Cellerant Therapeutics

Latest Information Update: 01 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cellerant Therapeutics
  • Class Cell therapies; Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Neutropenia

Most Recent Events

  • 22 Sep 2017 Cellerant Therapeutics completes a phase II trial for Neutropenia (Chemotherapy-induced) in USA (IV) (NCT02282215)
  • 08 Feb 2017 Phase-I development for Neutropenia (in patients undergoing cord blood transplantation) has been completed and preclinical development for Neutropenia (in acute radiation syndrome) is ongoing in USA
  • 08 Feb 2017 Romyelocel-L is still in phase II trials for Neutropenia (Chemotherapy-induced, in patients with acute myeloid leukaemia) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top